Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baoshentongluo Xiaobai prescription is a Traditional Chinese Medicine (TCM) herbal formula developed by the Beijing Hospital of Traditional Chinese Medicine, Capital Medical University. It is utilized as a component of the staged "Yishentongluo" therapy for the treatment of diabetic kidney disease (DKD). The prescription is specifically formulated to target and reduce proteinuria (indicated by the term "Xiaobai," which refers to eliminating white/proteinuria) and to slow the progression of renal function decline in patients with chronic kidney disease (CKD) stages 1 through 4. In clinical practice, it is typically administered as an adjunct to standard Western medical therapies to improve renal outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baoshentongluo Xiaobai prescription.